Minimally-invasive treatment options like transcatheter aortic valve replacement (TAVR) could be a good option for some patients because patients typically stay in the hospital for shorter periods of time.
Abbott Laboratories is paying $225M for the heart valve replacement developer Tendyne, and NuVasive is spending $13.5M in order to settle after false Medicare claim allegations.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.